Supernus Pharmaceuticals | SUPN - Capitaux Propres Et Réserves





Capitaux Propres Et Réserves Changement Date
Abbott USD 52.06B 69M 2026-03
ANI Pharmaceuticals USD 562.3M 21.58M 2026-03
Aurora Cannabis CAD 536.36M 30.74M 2025-12
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Canopy Growth CAD 758.17M 22.16M 2025-12
Cara Therapeutics USD 20.95M 6.92M 2025-12
Corcept Therapeutics USD 637.99M 9.82M 2026-03
Eisai JPY 889.64B 35.21B 2025-12
Eli Lilly USD 31.2B 4.66B 2026-03
Novo Nordisk DKK 203.07B 9.02B 2026-03
Pacira USD 653.89M 39.22M 2026-03
Perrigo USD 2.5B 436.7M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Supernus Pharmaceuticals USD 1.08B 15.09M 2026-03
United Therapeutics USD 5.9B 1.2B 2026-03
Xeris Pharmaceuticals USD 13.01M 678K 2026-03